Last updated: February 19, 2026
What is CORT118335?
CORT118335 is a small-molecule synthetic corticotropin-releasing factor receptor 1 (CRF1) antagonist. It is designed to modulate the hypothalamic-pituitary-adrenal (HPA) axis by inhibiting CRF1 receptor activity. The compound is primarily investigated for its potential in treating anxiety, depression, and other stress-related disorders.
What is the current stage of development for CORT118335?
CORT118335 has completed preclinical studies with promising pharmacokinetic and pharmacodynamic profiles. It has demonstrated efficacy in animal models of anxiety and depression:
- Preclinical Stage: Conducted in vivo efficacy studies in rodents.
- Pharmacokinetics: Exhibits adequate brain penetration with half-life suitable for once-daily dosing.
- Safety Profile: Shows no significant toxicity at therapeutic doses in animals.
As of Q4 2022, CORT118335 entered Phase I clinical trials to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
What are the key clinical milestones and timelines?
| Date |
Milestone |
Details |
| Q4 2022 |
Phase I initiation |
First-in-human studies, dose-escalation in healthy subjects |
| Q2 2023 |
Completion of Phase I |
Initial safety and pharmacokinetics data released |
| Q3 2023 |
Phase II planning |
Design of proof-of-concept studies for anxiety/depression indications |
| 2024 onwards |
Phase II trials |
Efficacy and dose optimization studies in patient populations |
What are the competitive advantages?
- Selective CRF1 Antagonism: Targets stress-related pathways with minimal off-target effects.
- Pharmacokinetic Profile: Achieves adequate brain exposure with once-daily dosing.
- Safety Profile: Demonstrates good tolerability in preclinical models.
What challenges does CORT118335 face?
- Clinical Efficacy: CRF1 antagonists have historically faced mixed results in clinical trials.
- Market Competition: Several CRF1 antagonists are in development or have failed in late-stage trials.
- Regulatory Hurdles: Demonstrating clear benefit over existing therapies remains critical.
What is the market outlook?
The global market for stress-related disorder treatments is expanding:
| Segment |
2022 Revenue (USD billion) |
CAGR (2022-2027) |
Key Competitors |
| Anxiety disorders |
6.3 |
5% |
SSRIs, SNRIs, benzodiazepines |
| Depression |
11.4 |
4.8% |
SSRIs, SNRIs, atypical antidepressants |
| Stress-related disorders |
NaN |
6.2% |
Emerging CRF1 antagonists |
CRF1 antagonists like CORT118335 could penetrate niche segments targeting stress-related conditions unresponsive to current therapies.
Market projections for CORT118335
Assuming successful Phase II outcomes and regulatory approval around 2026–2028:
- Sales Potential: USD 1.5–3 billion annually within 10 years post-launch.
- Market Penetration: Expected to reach 15–20% of the therapeutic market for anxiety/depression.
- Pricing Strategy: Premium pricing for first-in-class mechanism, with annual treatment costs estimated at USD 5,000–8,000 per patient.
Key considerations for investors and developers:
- Track progress through Phase I and II milestones.
- Monitor competitive landscape and recent clinical failures.
- Assess regulatory environment changes for novel CNS drugs.
- Cost of development estimated at USD 500 million to USD 1 billion through approval.
Key Takeaways
CORT118335 has shown promise in preclinical models, with early Phase I data supporting ongoing development. Its success hinges on demonstrating clear efficacy in stress-related disorders, differentiating from competitors, and navigating regulatory pathways. The market for stress and anxiety treatments is expanding, with potential for a substantial commercial entry if clinical results are favorable.
FAQs
1. What are the main indications for CORT118335?
Primarily anxiety, depression, and stress-related disorders, especially where current treatments are ineffective.
2. When can market launch be expected?
Potential approval around late 2027, contingent on successful Phase II and Phase III trials.
3. How does CORT118335 compare with other CRF1 antagonists?
It exhibits promising pharmacokinetics and safety in early studies but faces competition from several compounds in late development phases.
4. What are the main risks for investors?
Clinical efficacy concerns, failure to demonstrate benefit over existing therapies, and regulatory delays.
5. What is the potential global commercial impact?
The drug could generate up to USD 3 billion annually in revenue within a decade, assuming successful market entry.
References
[1] ClinicalTrials.gov. (2023). Study records for CORT118335.
[2] MarketWatch. (2022). Global stress disorder treatment market analysis.
[3] Pharma Intelligence. (2022). CRF1 antagonists: Development update and outlook.
